The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open …
MA Kass, DK Heuer, EJ Higginbotham… - Archives of …, 2002 - jamanetwork.com
Background Primary open-angle glaucoma (POAG) is one of the leading causes of
blindness in the United States and worldwide. Three to 6 million people in the United States
are at increased risk for developing POAG because of elevated intraocular pressure (IOP),
or ocular hypertension. There is no consensus on the efficacy of medical treatment in
delaying or preventing the onset of POAG in individuals with elevated IOP. Therefore, we
designed a randomized clinical trial, the Ocular Hypertension Treatment Study. Objective To …
blindness in the United States and worldwide. Three to 6 million people in the United States
are at increased risk for developing POAG because of elevated intraocular pressure (IOP),
or ocular hypertension. There is no consensus on the efficacy of medical treatment in
delaying or preventing the onset of POAG in individuals with elevated IOP. Therefore, we
designed a randomized clinical trial, the Ocular Hypertension Treatment Study. Objective To …